Iverson Genetic Diagnostics is a biotechnology and healthcare company founded in 2006 with the mission to provide diagnostic tools for the prevention and treatment of chronic diseases. The company's focus lies in developing advanced genetic tests for disease detection and treatment. Their portfolio includes a warfarin dosing panel, a high-risk HPV panel, and an MTHFR assay, catering to various conditions such as enzyme variations affecting warfarin response, coronary artery disease, thrombosis, heart attacks, and strokes. Headquartered in Bothell, Washington, Iverson Genetic Diagnostics aims to be the partner in diagnosing and treating chronic diseases, providing precise medical care through their innovative genetic testing solutions.
The company secured a $20.00K Debt Financing investment on 09 October 2014, enabling them to further their research and development efforts in the domain of genetic diagnostics. With a clear focus on addressing the growing need for personalized medicine, Iverson Genetic Diagnostics stands as a promising player in the healthcare industry, poised to make significant contributions in the field of genetic disease diagnosis and treatment.
